FDA Accepts Supplement for Nizoral Anti-Dandruff Application
The FDA has accepted a supplemental application for Nizoral Anti-Dandruff, containing ketoconazole.
Published: August 1, 2026
Updated: August 1, 2026
Author: Humanexa Intelligence
Therapeutic area: Dermatology / Anti-fungal
Company: Anti-fungal
Asset: KRAMER
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Anti-fungal
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for Nizoral Anti-Dandruff is a significant regulatory milestone that could strengthen KRAMER's market position. Competitors with similar products may need to reassess their strategies in light of this development.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for the FDA's review process and any subsequent approval announcements.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.